BS Wake Forest University
MBA University of Michigan
Mr. Scibetta joined ImmuneID as Chief Executive Officer in September 2021 and brings over 20 years of experience successfully leading life science companies from early-stage platform development through commercialization. He joins ImmuneID after serving as CEO and a member of the Board of Directors of Maverick Therapeutics Inc., a biotechnology company pioneering conditionally active bispecific T-cell targeted immunotherapies with their COBRA Platform. Maverick was acquired by Takeda in April 2021. Prior to Maverick, Mr. Scibetta held various executive leadership roles at Pacira Pharmaceuticals (Nasdaq: PCRX), including President, and before that as CFO, overseeing global R&D, CMC, and capacity expansion activities for the development of their drug EXPAREL. He successfully led the company’s 2011 IPO and subsequent debt and equity financings. Prior to Pacira, Mr. Scibetta served as CFO of Bioenvision Inc. (NASD: BVIN, acquired by Genzyme) and Merrimack Pharmaceuticals. He began his career in investment banking, spending over a decade sourcing and executing transactions for a range of public and private healthcare and life sciences companies.
Mr. Scibetta holds a BS in Physics from Wake Forest University and an MBA from the University of Michigan. He currently serves on the Board of Aquestive Therapeutics (NASDAQ: AQST) and Matinas BioPharma (NYSE: MTNB).
BS University of Vermont
MBA Harvard Business School
Mr. Jeff Capello is a senior finance executive with over 30 years of experience helping companies create significant value for their shareholders. Mr. Capello started his career in public accounting with PricewaterhouseCoopers where he was an audit partner on a variety of assignments ranging from helping startup companies through the public offering process to helping larger companies with strategic, transaction and operational support projects. He also served as the Chief Financial Officer for a range of publicly held and private equity backed companies (PerkinElmer, Boston Scientific, Ortho Clinical Diagnostic, Beacon Health Options and Biogen) where he developed a strong record of improving the operational and financial health of these organizations. Mr. Capello’s specific areas of expertise include strategic planning, business development, capital markets, business planning, cost management, productivity improvement, functional leadership, people development and organizational design. He also served on the Board of Directors for several early stage publicly held biotech companies as Audit Committee Chair. Mr. Capello has a Master’s in Business Administration from the Harvard Business School and a Bachelor of Science in Business Administration. He also was a Certified Public Accountant in Massachusetts.
Managing Partner, Pitango Healthtech Fund
BSc Ben-Gurion University
Ittai currently serves on the Board of Directors of DouxMatok, EarlySense, Medisafe, Clew Medical, Tscan, Vertos Medical and Visby Medical. He also serves as the Chairman of the Board at EarlySense.
His investments focus on Digital Health, Health-IT and MedTech, and he brings with him over 15 years of experience in Venture Capital as well as 20 years of experience in operations and management roles.
Before joining Pitango, Ittai headed Corporate Development at Nektar Therapeutics (NASDAQ: NKTR), served as Executive Vice President roles at IDGene Pharmaceuticals and IDEXX Laboratories (NASDAQ: IDXX).
Ittai holds a BSc in Chemical Engineering and Biotechnology from Ben-Gurion University, and an MBA from the MIT Sloan School of Management.
Managing Partner, Section 32
BA Stanford University
PhD Harvard University
Dr. Steve Kafka works with exceptional scientists and entrepreneurs to help build companies that seek to create vast improvements in patient care and rewarding professional opportunities for employees.
Dr. Kafka co-led investment and served as both founding CEO and Executive Chairman of Thrive Earlier Detection, a healthcare company advancing a breakthrough blood test for the earlier detection of multiple types of cancer. Thrive was acquired by Exact Sciences in January 2021. Steve also served as Executive Chairman at the molecular technology company ArcherDX, Inc., which was acquired by Invitae in October 2020. Dr. Kafka also led Section 32’s investments in C2i Genomics, CelsiusTx, and Glympse Bio where he is also Chairman.
Earlier, Dr. Kafka was President and Chief Operating Officer at Foundation Medicine, which was acquired by Roche in 2018, and also held leadership roles with several biotechnology companies.
Dr. Kafka holds a PhD degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.
Managing Partner, Alta Partners
BA Georgetown University
MBA University of California, Los Angeles
Dan Janney is the Managing Partner of Alta Partners. Dan Janney joined Alta Partners at its founding in 1996. He has nearly 25 years of successful early-stage investing experience in life sciences. Dan’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities.
Dan is currently on the board of directors of several public and private companies, including Allakos (NASDAQ:ALLK), Be Biopharma, Curasen Therapeutics, ImmuneID, Krystal Biotech (NASDAQ:KYRS), Lassen Therapeutics, Novome Biotechnologies, and Prolacta Bioscience. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ:CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Esperion Therapeutics (NASDAQ:ESPR), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
Dan is a member of The President’s Council of the J. David Gladstone Institutes and the chair of the Board of Directors of the California Academy of Sciences. He also serves on the Board of Regents of Georgetown University. He holds a BA from Georgetown University and a MBA from the Anderson School at the University of California, Los Angeles.